A Comparative Study of Sugammadex versus Neostigmine for Reversal of Vecuronium-Induced Neuromuscular Blockade Following Intracranial Tumor Resection Surgery In Adults

Introduction:Intracranial surgeries demand precise neuromuscular control to ensure optimal conditions and minimize patient movement. Traditional reversal agents like Neostigmine may have limitations, prompting the investigation of Sugammadex, which offers rapid and specific reversal of neuromuscular blockade induced by agents like Vecuronium.Objective: This study aims to compare the efficacy, safety, and speed of recovery between Sugammadex and Neostigmine in reversing Vecuronium-induced neuromuscular blockade following intracranial surgery.Methods: A prospective, randomized controlled trial will be conducted on adults undergoing intracranial tumor resection surgery. Patients will be randomly allocated to receive either Sugammadex (2mg/kg) or Neostigmine (0.05mg/kg) for neuromuscular blockade reversal. Various parameters including time to reversal, incidence of residual blockade, recovery of neuromuscular function, and safety outcomes will be assessed.Results: A total of 50 patients will be included, with 25 in each group. Primary outcomes include time taken for reversal of neuromuscular blockade, while secondary outcomes encompass residual blockade incidence, neuromuscular function recovery, and safety profiles.Conclusion: This study will provide valuable insights into the comparative efficacy and safety of Sugammadex and Neostigmine in reversing Vecuronium-induced neuromuscular blockade following intracranial surgery. Findings will contribute to optimizing anesthesia practices, enhancing patient outcomes, and minimizing postoperative complications in this critical surgical setting.